BRTX
BioRestorative Therapies Inc

3,413
Mkt Cap
$9.23M
Volume
42,133.00
52W High
$2.50
52W Low
$0.9841
PE Ratio
-0.69
BRTX Fundamentals
Price
$1.04
Prev Close
$1.02
Open
$1.04
50D MA
$1.13
Beta
1.19
Avg. Volume
22,986.10
EPS (Annual)
-$1.16
P/B
3.78
Rev/Employee
$36,454.54
Loading...
Loading...
News
all
press releases
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Down 2.6% - Here's Why
BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Down 2.6% - Time to Sell...
MarketBeat·18d ago
News Placeholder
More News
News Placeholder
BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Down 1.8% - Should You Sell?
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Down 1.8% - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Down 2.7% - Time to Sell?
BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Down 2.7% - Here's Why...
MarketBeat·2mo ago
News Placeholder
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Up 6.4% - What's Next?
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Up 6.4% - Here's What Happened...
MarketBeat·3mo ago
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 0.00% and -97.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Earnings Outlook For BioRestorative Therapies
read more...
Benzinga·3mo ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +11.36% and -86.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·6mo ago
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +26.83% and +51.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
<
1
2
...
>

Latest BRTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.